SIBO, Probiotics, and Your Gut Health: A Long-Term Strategy
- Treating SIBO With Probiotics|
- The SIBO-IBS Link|
- Your SIBO Treatment Plan|
- SIBO Probiotics Tips|
- Other SIBO Treatments|
- Extra Benefits of Treatment|
- Probiotics Are Effective|
- Recommended Products|
You may have read internet advice that suggests you should never take probiotics if you have small intestinal bacterial overgrowth (SIBO). Since the condition is caused by an excess of bacteria (including beneficial bacteria) in the small intestine, why would you add more?
However, if you follow that advice, you’d be missing out on a research-backed, effective treatment.
Let’s discuss how following the research can enable you to overcome SIBO by using probiotics and other safe, effective therapies.
Treating SIBO With Probiotics
Even though it may seem counter-intuitive, research CLEARLY shows that probiotics can be very effective for treating SIBO, improving both symptoms and lab values 1.
- One SIBO-probiotics study found probiotics to be more effective than Metronidazole, an antibiotic treatment for SIBO 2.
- A meta-analysis summarizing 18 clinical trials concluded that probiotics are an effective treatment for SIBO 3. Specifically, probiotics reduce bacterial overgrowth and hydrogen concentrations, and improve symptoms, including abdominal pain.
- Another study found that probiotics work much better in patients with both IBS and SIBO, as compared to those who have IBS without SIBO 4.
The SIBO-IBS Link
Before we dive into other research-backed treatments for SIBO, it’s important to clarify the link between SIBO and irritable bowel syndrome (IBS).
SIBO is not a “condition” in itself. It is, in fact, a lab finding, usually based on a glucose or lactulose breath test. It’s possible to test positive for SIBO and be perfectly healthy, without symptoms.
IBS is not exactly a “condition” either, it is a set of digestive symptoms that include bloating, abdominal pain, diarrhea and/or constipation. There is no test for IBS. Patients who test positive for SIBO may have IBS symptoms.
SIBO is a potential cause of IBS. However, it is not the only possible cause. A recent meta-analysis (highest quality research) reviewed 50 clinical studies and found that:
- More than one-third of IBS patients tested positive for SIBO 5.
- IBS patients were nearly five times more likely to test positive for SIBO compared to healthy controls 6.
SIBO falls under a broader umbrella term of digestive tract dysbiosis. Dysbiosis, simply stated, means an imbalance of bacteria, fungus, and other organisms of the digestive system. Most treatments that work for dysbiosis also work for SIBO.
Probiotics and Your SIBO Treatment Plan
When it comes to treatment of SIBO, quick fixes don’t always work. Long-term success is possible, however, through a combination of treatments that address intestinal dysbiosis and improve digestive health. This may include probiotics 7, diet 8, fasting 9, digestive supports 10, and herbal antimicrobials 11. All of these treatments are supported by research.
Every SIBO patient has a unique intestinal microbiome and the best combination of SIBO treatments for one may not be the best for another. What will work for you can only be learned through a process of personal experimentation.
Probiotic supplements are an excellent place to start in your personalized SIBO treatment plan. They are simple to use, safe over the long term 12 13, and backed by research. In fact, while the research described above supports using probiotics for SIBO, there’s even more research to support using probiotics for IBS symptoms 14 15 16 17.
As I discuss more fully in my book Healthy Gut, Healthy You, probiotics are a very important foundational strategy for treating IBS and other digestive problems.
SIBO Probiotics Tips
Though there are hundreds of probiotic supplements on the market, most probiotics fall into one of these three categories:
- Lactobacillus and Bifidobacteria blends
- Saccharomyces boulardii (a beneficial yeast)
- Soil-based probiotics, usually Bacillus species
IBS research has concluded that multispecies probiotics work better for IBS 18 19. Using one type of probiotic is good, but using all three different probiotics together allows them to work synergistically to improve your gut health.
The three types of probiotics work together like the legs of a three-legged stool. If the stool only has one or two legs, it’s likely to be unstable. With three legs, the stool is able to stay upright.
Choose high quality probiotic supplements with a high count of CFU (colony forming units). Keep in mind that probiotic manufacturing is not well-regulated and some labels’ claims do not stand up to scrutiny 20 21 22. Look for:
- A clearly stated list of probiotic species
- A clearly stated number of colony-forming units (CFUs) in the billions
- A manufacture date and/or expiration date
- Labeled free of common allergens and other substances you may wish to avoid (e.g. gluten-free, non-GMO, vegan)
- Good Manufacturing Practices (GMP) certification
- Lab-verified for probiotic species and potency by third-party analysis (independent lab testing)
Other SIBO Treatments
Here are some other treatments that you may want to try. Go slowly, try them one at a time, and assess their impact on your SIBO symptoms. If after a few weeks, you don’t see a difference in your symptoms, discontinue that treatment. How your body responds is more important than breath test results.
Low FODMAP Diet
Diets that restrict bacteria-feeding carbs have been shown to improve SIBO and IBS symptoms 23 24 25 26. These are known as low FODMAP diets.
One review of 10 clinical trials found that the low FODMAP diet led to clinical response in 50%–80% of patients with IBS symptoms 27. This review also found that the low FODMAP diet results in profound changes in the microbiota and in overall gut health. It reduces leaky gut, inflammation and histamine (a marker of an overzealous immune system).
Digestive Supports
Adequate stomach acid (HCI) production is crucial for the digestive process and helps to keep bad bacteria in check. Some people don’t produce enough stomach acid for proper digestion.
Research into the long-term effects of proton pump inhibitors (drugs that lower stomach acid) gives us some insights into the risks of low HCI production 28 29 30. Inadequate stomach acid is one of the risk factors for SIBO and fungal infections in the small intestine (SIFO).
Digestive enzymes are also crucial for the digestive process. Anyone who eats a standard American diet, may not be getting enough digestive enzymes from their diet.
While there are no clinical studies for digestive enzymes and SIBO, we can look at the research more broadly and see that digestive enzymes may contribute to the overall goal of improving digestive health 31 32.
Supplemental HCI and digestive enzymes are available separately or in combination formulas.
Prokinetics are agents that support healthy motility in your stomach and intestines. Motility means that food moves through your intestinal tract at the right pace. Motility keeps your intestinal ecosystem in balance, much like flowing water of a river or stream. Stagnant pond water fosters bacterial growth and the same is true of food in your digestive system.
Antimicrobial Therapy
A standard SIBO treatment is antibiotic therapy with Rifaximin, which reduces unwanted gut bacteria in both the small and large intestine. Research shows that this approach eliminates SIBO for 67% of patients 33.
Herbal antimicrobials work in the same way as Rifaximin and are more commonly used in functional medicine. There are fewer studies for herbal antimicrobials, but they have been shown effective in IBS and SIBO 34 35.
Many of these herbal medicines also have beneficial side effects. They are anti-inflammatory and perhaps even antidepressant 36 37. Herbals may also combat other bacterial and fungal imbalances that might not have been detected through testing, such as candida overgrowth 38. Many herbal medicines act against bacteria, fungi, and protozoa while antibiotics mostly work against bacteria.
Anecdotal evidence suggests that, long-term, some patients relapse after antimicrobial and antibiotic therapy. For some SIBO patients, there may be underlying causes that allow unwanted gut flora to repopulate the small bowel.
This is where an ongoing strategy for digestive health can provide better long-term results when compared to one single, short-term treatment. A personalized approach that may include probiotics, dietary changes, digestive aids, and antimicrobial treatment may work better in the long run for keeping gastrointestinal symptoms in check.
Elemental Diet
Elemental diets were developed as a medical food to treat patients with severe digestive issues. This dietary product is essentially a fast for your gut microbes. Drinking elemental shakes for 2-3 weeks, with no other sources of calories, often achieves results when other gut therapies have failed.
Research into elemental diets has focused on inflammatory bowel disease 39 40 41 42 43 44 45 46 47 48 49. We don’t yet have a lot of research into elemental diets and SIBO. However, one exciting study saw lactulose breath tests normalize in 80% of SIBO patients after two weeks on the elemental diet 50. Sixty-five percent of patients in the same study saw an improvement in their IBS symptoms.
Elemental meal replacement shakes can be used in flexible ways to manage SIBO symptoms. Even a “half” elemental diet (up to 50% of daily calories from elemental shakes) reduces gut symptoms and flares 51. Elemental meal replacement shakes can be an effective part of a long-term SIBO management strategy.
The Extra Benefits of Treating SIBO
If you have been struggling with IBS symptoms, getting them under control is a big win. Even better, by treating digestive tract dysbiosis, including SIBO, you may experience beneficial effects on other health conditions.
Research shows that successful SIBO treatments can also lead to improvements in:
- Rosacea 52
- Restless Leg Syndrome 53 54
- Blood sugar, cholesterol, and potentially weight 55 56 57
- Depression (improved by probiotics) 58 59 60
- Rheumatoid arthritis 61
- Non-responsive Celiac disease 62
SIBO is also associated with a number of other conditions, including: hypothyroid 63, coronary artery disease 64, diabetes 65, chronic kidney disease 66, chronic pancreatitis 67, and Parkinson’s disease 68.
We don’t yet have research to show if SIBO treatments can help to resolve these conditions.
Probiotics Are Effective for SIBO
Be wary of internet advice that suggests probiotics will make SIBO worse. This is one area where, sadly, opinion has drifted away from science. Probiotics are an effective treatment for SIBO and can be used alone or in combination with a number of other research-backed treatments.
SIBO patients may benefit most from a long-term strategy to improve overall digestive health rather than short-term, SIBO-focused treatments. This approach has benefits beyond treating SIBO and can help resolve digestive symptoms, non-digestive symptoms, and chronic inflammatory conditions.
Dr. Michael Ruscio is a DC, natural health provider, researcher, and clinician. He serves as an Adjunct Professor at the University of Bridgeport and has published numerous papers in scientific journals as well as the book Healthy Gut, Healthy You. He also founded the Ruscio Institute of Functional Health, where he helps patients with a wide range of GI conditions and serves as the Head of Research.➕ References
-
Zhong C, Qu C, Wang B, Liang S, Zeng B. Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth: A Meta-Analysis and Systematic Review of Current Evidence. J Clin Gastroenterol. 2017;51(4):300-311. doi:10.1097/MCG.0000000000000814
-
Soifer LO, Peralta D, Dima G, Besasso H. Eficacia comparativa de un probiótico vs un antibiótico en la respuesta clínica de pacientes con sobrecrecimiento bacteriano del intestino y distensión abdominal crónica funcional: un estudio piloto [Comparative clinical efficacy of a probiotic vs. an antibiotic in the treatment of patients with intestinal bacterial overgrowth and chronic abdominal functional distension: a pilot study]. Acta Gastroenterol Latinoam. 2010;40(4):323-327.
-
Zhong C, Qu C, Wang B, Liang S, Zeng B. Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth: A Meta-Analysis and Systematic Review of Current Evidence. J Clin Gastroenterol. 2017;51(4):300-311. doi:10.1097/MCG.0000000000000814
-
Leventogiannis K, Gkolfakis P, Spithakis G, et al. Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth [published correction appears in Probiotics Antimicrob Proteins. 2018 Mar 28;:]. Probiotics Antimicrob Proteins. 2019;11(2):627-634. doi:10.1007/s12602-018-9401-3
-
Chen B, Kim JJ, Zhang Y, Du L, Dai N. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol. 2018;53(7):807-818. doi:10.1007/s00535-018-1476-9
-
Chen B, Kim JJ, Zhang Y, Du L, Dai N. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol. 2018;53(7):807-818. doi:10.1007/s00535-018-1476-9
-
Zhong C, Qu C, Wang B, Liang S, Zeng B. Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth: A Meta-Analysis and Systematic Review of Current Evidence. J Clin Gastroenterol. 2017;51(4):300-311. doi:10.1097/MCG.0000000000000814
-
Staudacher HM, Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. Gut. 2017;66(8):1517-1527. doi:10.1136/gutjnl-2017-313750
-
Pimentel M, Constantino T, Kong Y, Bajwa M, Rezaei A, Park S. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Dig Dis Sci. 2004;49(1):73-77. doi:10.1023/b:ddas.0000011605.43979.e1
-
Jacobs C, Coss Adame E, Attaluri A, Valestin J, Rao SS. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment Pharmacol Ther. 2013;37(11):1103-1111. doi:10.1111/apt.12304
-
Chedid V, Dhalla S, Clarke JO, et al. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. 2014;3(3):16-24. doi:10.7453/gahmj.2014.019
- Office of Dietary Supplements – Probiotics. National Institutes of Health. 2020. https://ods.od.nih.gov/factsheets/Probiotics-HealthProfessional/
-
Bafeta A, Koh M, Riveros C, Ravaud P. Harms Reporting in Randomized Controlled Trials of Interventions Aimed at Modifying Microbiota: A Systematic Review. Ann Intern Med. 2018;169(4):240-247. doi:10.7326/M18-0343
-
Yuan F, Ni H, Asche CV, Kim M, Walayat S, Ren J. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Curr Med Res Opin. 2017;33(7):1191-1197. doi:10.1080/03007995.2017.1292230
-
Tiequn B, Guanqun C, Shuo Z. Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: a meta-analysis. Intern Med. 2015;54(3):243-249. doi:10.2169/internalmedicine.54.2710
-
McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol. 2008;14(17):2650-2661. doi:10.3748/wjg.14.2650
-
Martoni CJ, Srivastava S, Leyer GJ. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. Nutrients. 2020;12(2):363. Published 2020 Jan 30. doi:10.3390/nu12020363
-
American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ, Chey WD, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104 Suppl 1:S1-S35. doi:10.1038/ajg.2008.122
-
Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109(10):1547-1562. doi:10.1038/ajg.2014.202
- Viktoria Yonkova Marinova, Iliyana Kirilova Rasheva, Yoana Krasimirova Kizheva, Yordanka Dimitrova Dermenzhieva & Petya Koitcheva Hristova (2019) Microbiological quality of probiotic dietary supplements, Biotechnology & Biotechnological Equipment, 33:1, 834-841, DOI: 10.1080/13102818.2019.1621208
- https://labdoor.com/rankings/probiotics
-
Staudacher HM, Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. Gut. 2017;66(8):1517-1527. doi:10.1136/gutjnl-2017-313750
-
Marsh A, Eslick EM, Eslick GD. Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. Eur J Nutr. 2016;55(3):897-906. doi:10.1007/s00394-015-0922-1
-
Schumann D, Klose P, Lauche R, Dobos G, Langhorst J, Cramer H. Low fermentable, oligo-, di-, mono-saccharides and polyol diet in the treatment of irritable bowel syndrome: A systematic review and meta-analysis. Nutrition. 2018;45:24-31. doi:10.1016/j.nut.2017.07.004
-
Altobelli E, Del Negro V, Angeletti PM, Latella G. Low-FODMAP Diet Improves Irritable Bowel Syndrome Symptoms: A Meta-Analysis. Nutrients. 2017;9(9):940. Published 2017 Aug 26. doi:10.3390/nu9090940
-
Staudacher HM, Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. Gut. 2017;66(8):1517-1527. doi:10.1136/gutjnl-2017-313750
-
Jacobs C, Coss Adame E, Attaluri A, Valestin J, Rao SS. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment Pharmacol Ther. 2013;37(11):1103-1111. doi:10.1111/apt.12304
-
Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010;8(6):504-508. doi:10.1016/j.cgh.2009.12.022
-
Chubineh S, Birk J. Proton pump inhibitors: the good, the bad, and the unwanted. South Med J. 2012;105(11):613-618. doi:10.1097/SMJ.0b013e31826efbea
-
Ianiro G, Pecere S, Giorgio V, Gasbarrini A, Cammarota G. Digestive Enzyme Supplementation in Gastrointestinal Diseases. Curr Drug Metab. 2016;17(2):187-193. doi:10.2174/13892002170216011415013
-
Spagnuolo R, Cosco C, Mancina RM, et al. Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2017;21(2 Suppl):102-107.
-
Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther. 2017;45(5):604-616. doi:10.1111/apt.13928
-
Chen C, Tao C, Liu Z, et al. A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome. Phytother Res. 2015;29(11):1822-1827. doi:10.1002/ptr.5475
-
Chedid V, Dhalla S, Clarke JO, et al. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. 2014;3(3):16-24. doi:10.7453/gahmj.2014.019
-
Rahimi R, Nikfar S, Abdollahi M. Induction of clinical response and remission of inflammatory bowel disease by use of herbal medicines: a meta-analysis. World J Gastroenterol. 2013;19(34):5738-5749. doi:10.3748/wjg.v19.i34.5738
- Mechan, A., Fowler, A., Seifert, N., Rieger, H., Wöhrle, T., Etheve, S., . . . Mohajeri, M. (2011). Monoamine reuptake inhibition and mood-enhancing potential of a specified oregano extract. British Journal of Nutrition, 105(8), 1150-1163. doi:10.1017/S0007114510004940
-
Banik GD, De A, Som S, et al. Hydrogen sulphide in exhaled breath: a potential biomarker for small intestinal bacterial overgrowth in IBS. J Breath Res. 2016;10(2):026010. Published 2016 May 10. doi:10.1088/1752-7155/10/2/026010
-
Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children. J Pediatr Gastroenterol Nutr. 2000;31(1):8-15. doi:10.1097/00005176-200007000-00005
-
Rajendran N, Kumar D. Role of diet in the management of inflammatory bowel disease. World J Gastroenterol. 2010;16(12):1442-1448. doi:10.3748/wjg.v16.i12.1442
-
Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006;4(6):744-753. doi:10.1016/j.cgh.2006.03.010
-
Berni Canani R, Terrin G, Borrelli O, et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn’s disease. Dig Liver Dis. 2006;38(6):381-387. doi:10.1016/j.dld.2005.10.005
-
Knight C, El-Matary W, Spray C, Sandhu BK. Long-term outcome of nutritional therapy in paediatric Crohn’s disease. Clin Nutr. 2005;24(5):775-779. doi:10.1016/j.clnu.2005.03.005
-
Tsertsvadze A, Gurung T, Court R, Clarke A, Sutcliffe P. Clinical effectiveness and cost-effectiveness of elemental nutrition for the maintenance of remission in Crohn’s disease: a systematic review and meta-analysis. Health Technol Assess. 2015;19(26):1-138. doi:10.3310/hta19260
-
Nakahigashi M, Yamamoto T, Sacco R, Hanai H, Kobayashi F. Enteral nutrition for maintaining remission in patients with quiescent Crohn’s disease: current status and future perspectives. Int J Colorectal Dis. 2016;31(1):1-7. doi:10.1007/s00384-015-2348-x
-
Day AS, Whitten KE, Sidler M, Lemberg DA. Systematic review: nutritional therapy in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2008;27(4):293-307. doi:10.1111/j.1365-2036.2007.03578.x
-
Heuschkel R. Enteral nutrition should be used to induce remission in childhood Crohn’s disease. Dig Dis. 2009;27(3):297-305. doi:10.1159/000228564
-
Verma S, Brown S, Kirkwood B, Giaffer MH. Polymeric versus elemental diet as primary treatment in active Crohn’s disease: a randomized, double-blind trial. Am J Gastroenterol. 2000;95(3):735-739. doi:10.1111/j.1572-0241.2000.01527.x
-
Hiwatashi N. Enteral nutrition for Crohn’s disease in Japan. Dis Colon Rectum. 1997;40(10 Suppl):S48-S53. doi:10.1007/BF02062020
-
Pimentel M, Constantino T, Kong Y, Bajwa M, Rezaei A, Park S. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Dig Dis Sci. 2004;49(1):73-77. doi:10.1023/b:ddas.0000011605.43979.e1
- Takagi S, Utsunomiya K, Kuriyama S, et al. Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn’s disease: A randomized-controlled trial. Aliment Pharmacol Ther. 2006;24(9):1333-1340. doi:10.1111/j.1365-2036.2006.03120.x
-
Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol. 2008;6(7):759-764. doi:10.1016/j.cgh.2008.02.054
-
Weinstock LB, Fern SE, Duntley SP. Restless legs syndrome in patients with irritable bowel syndrome: response to small intestinal bacterial overgrowth therapy. Dig Dis Sci. 2008;53(5):1252-1256. doi:10.1007/s10620-007-0021-0
-
Weinstock LB, Walters AS. Restless legs syndrome is associated with irritable bowel syndrome and small intestinal bacterial overgrowth. Sleep Med. 2011;12(6):610-613. doi:10.1016/j.sleep.2011.03.007
-
Mathur R, Chua KS, Mamelak M, et al. Metabolic effects of eradicating breath methane using antibiotics in prediabetic subjects with obesity. Obesity (Silver Spring). 2016;24(3):576-582. doi:10.1002/oby.21385
-
Basseri RJ, Basseri B, Pimentel M, et al. Intestinal methane production in obese individuals is associated with a higher body mass index. Gastroenterol Hepatol (N Y). 2012;8(1):22-28.
-
Mathur R, Amichai M, Chua KS, Mirocha J, Barlow GM, Pimentel M. Methane and hydrogen positivity on breath test is associated with greater body mass index and body fat. J Clin Endocrinol Metab. 2013;98(4):E698-E702. doi:10.1210/jc.2012-3144
-
Ng QX, Peters C, Ho CYX, Lim DY, Yeo WS. A meta-analysis of the use of probiotics to alleviate depressive symptoms. J Affect Disord. 2018;228:13-19. doi:10.1016/j.jad.2017.11.063
-
Huang R, Wang K, Hu J. Effect of Probiotics on Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. 2016;8(8):483. Published 2016 Aug 6. doi:10.3390/nu8080483
-
Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M, et al. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. Nutrition. 2016;32(3):315-320. doi:10.1016/j.nut.2015.09.003
-
Podas T, Nightingale JM, Oldham R, Roy S, Sheehan NJ, Mayberry JF. Is rheumatoid arthritis a disease that starts in the intestine? A pilot study comparing an elemental diet with oral prednisolone. Postgrad Med J. 2007;83(976):128-131. doi:10.1136/pgmj.2006.050245
-
Tursi A, Brandimarte G, Giorgetti G. High prevalence of small intestinal bacterial overgrowth in celiac patients with persistence of gastrointestinal symptoms after gluten withdrawal. Am J Gastroenterol. 2003;98(4):839-843. doi:10.1111/j.1572-0241.2003.07379.x
-
Patil AD. Link between hypothyroidism and small intestinal bacterial overgrowth. Indian J Endocrinol Metab. 2014;18(3):307-309. doi:10.4103/2230-8210.131155
-
Fialho A, Fialho A, Kochhar G, et al. Association Between Small Intestinal Bacterial Overgrowth by Glucose Breath Test and Coronary Artery Disease. Dig Dis Sci. 2018;63(2):412-421. doi:10.1007/s10620-017-4828-z
-
Fialho A, Fialho A, Kochhar G, et al. Association Between Small Intestinal Bacterial Overgrowth by Glucose Breath Test and Coronary Artery Disease. Dig Dis Sci. 2018;63(2):412-421. doi:10.1007/s10620-017-4828-z
-
Fialho A, Fialho A, Kochhar G, et al. Association Between Small Intestinal Bacterial Overgrowth by Glucose Breath Test and Coronary Artery Disease. Dig Dis Sci. 2018;63(2):412-421. doi:10.1007/s10620-017-4828-z
-
Ní Chonchubhair HM, Bashir Y, Dobson M, Ryan BM, Duggan SN, Conlon KC. The prevalence of small intestinal bacterial overgrowth in non-surgical patients with chronic pancreatitis and pancreatic exocrine insufficiency (PEI). Pancreatology. 2018;18(4):379-385. doi:10.1016/j.pan.2018.02.010
-
Fu P, Gao M, Yung KKL. Association of Intestinal Disorders with Parkinson’s Disease and Alzheimer’s Disease: A Systematic Review and Meta-Analysis. ACS Chem Neurosci. 2020;11(3):395-405. doi:10.1021/acschemneuro.9b00607
Discussion
I care about answering your questions and sharing my knowledge with you. Leave a comment or connect with me on social media asking any health question you may have and I just might incorporate it into our next listener questions podcast episode just for you!